EUVIMEDEUVIMED entdecken
Crossref

Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency

Teresa S Chai, Linda H Rodgers-Fouche iD, Jenna O Walls, Anthony R Mattia, Daniel C Chung

Cancer · 2024

DOI: 10.1002/cncr.35473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Teresa S Chai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Testing, DNA Mismatch Repair, Colorectal Neoplasms, Hereditary Nonpolyposis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2017, the Food and Drug Administration approved pembrolizumab for treatment of any mismatch repair–deficient (dMMR) tumor making MMR immunohistochemistry (IHC) testing beneficial for all tumor types. For the first time, MMR IHC was not performed exclusively to screen for Lynch syndrome (LS).

Methods

In this study, all MMR IHC reports issued between 2017 and 2021 at an academic hospital were reviewed and completion of genetic testing was determined through chart review. Colorectal cancers (CRCs), endometrial cancers (ECs), and noncancerous lesions were excluded.

Results

Between 2017 and 2021, MMR IHC was completed in 1939 patients with a malignancy other than CRC or EC. Absent or weak staining for at least one MMR protein was detected in 115 (5.9%) patients and 59 (51%) of those completed germline genetic testing. Overall, the identification rate of LS in this cohort was 0.72%, which is similar to the rate in our previously reported CRC and EC universal screening cohort. A diagnosis of LS was most commonly made in patients with dMMR brain (18.75%) and small intestinal cancers (10.20%). Five additional patients were found to carry a pathogenic variant in a non‐LS gene.

Conclusions

Pan‐cancer MMR testing for pembrolizumab consideration can identify LS cases at a rate similar to universal CRC and EC screening programs. A persistent challenge is subsequent uptake of genetic testing. MMR testing should be prioritized in brain and small intestinal tumors, and multigene panel testing is recommended in patients with dMMR, as unexpected pathogenic variants in non‐LS genes were found as frequently as LS gene variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingDNA Mismatch RepairColorectal Neoplasms, Hereditary NonpolyposisHumansFemaleMaleMiddle AgedAgedAdultBrain NeoplasmsImmunohistochemistryAged, 80 and overAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Lynch syndromeMMR IHCpembrolizumabuniversal screening

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Linda H Rodgers-Fouche

Zitieren

APA

Chai, T. S., Rodgers-Fouche, L. H., Walls, J. O., Mattia, A. R., & Chung, D. C. (2024). Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency. Cancer. https://doi.org/10.1002/cncr.35473

Vancouver

Chai TS, Rodgers-Fouche LH, Walls JO, Mattia AR, Chung DC. Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency. Cancer. 2024. doi:10.1002/cncr.35473

BibTeX
@article{Chai2024,
  author = {Chai, Teresa S and Rodgers-Fouche, Linda H and Walls, Jenna O and Mattia, Anthony R and Chung, Daniel C},
  title = {Real‐world genetic testing outcomes of pan‐cancer testing for mismatch repair deficiency},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35473}
}
Kostenlos starten →